IL23A
Interleukin-23 subunit alpha
As of the edition of 20 October 2026, IL23A (interleukin-23 subunit alpha, UniProt Q9NPF7) has 9 drugs tested at it and 12 companies on the list, 1 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NPF7
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 15
- Disease areas
- Skin and connective tissue; Digestive system; Bones, joints and muscles; Immune system; Inherited and neonatal; Infections; Cancer; Heart and blood vessels
- Registered trials of its drugs
- 271
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Guselkumab | Marketed | Phase 4 | Ends 2029 |
| Risankizumab | Marketed | Phase 4 | Ends 2031 |
| Mirikizumab | Marketed | Phase 4 | Ends 2035 |
| Tildrakizumab | Marketed | Phase 4 | Ends 2030 |
| Brazikumab | Stopped | Phase 3 | none listed |
| IBI112 | Active | Phase 3 | none listed |
| GNR-068 | Active | Phase 3 | none listed |
| AVT04 | Status not established | Phase 3 | none listed |
| LY2525623 | Stopped | Phase 2 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 4 |
| Engaged | 5 |
| Undetermined | 2 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| AbbVie | Route B |
| AstraZeneca | Route A |
The other 9 companies at IL23A
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at IL23A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.